 "A. fumigatus", the most commonly infecting species, is intrinsically resistant to fluconazole.Aspergillosis is thought to affect more than 14 million people worldwide, with allergic bronchopulmonary aspergillosis (ABPA, >4 million), severe asthma with fungal sensitization (>6.5 million), and chronic pulmonary aspergillosis (CPA, ∼3 million) being considerably more prevalent than invasive aspergillosis (IA, >300,000).Other common conditions include Aspergillus bronchitis, "Aspergillus" rhinosinusitis (many millions), otitis externa, and "Aspergillus" onychomycosis (10 million).